Endothelin in coronary artery disease and myocardial infarction

Cardiology in Review

Volumn 21, Issue 5, 2013, Pages 249-256

  Kolettis, Theofilos M ^a   Barton, Matthias ^b   Langleben, David ^c   Matsumura, Yasuo ^d  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c MCGILL UNIVERSITY   (Canada)

^d OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

arrhythmia; atherosclerosis; endothelin; heart failure; myocardial infarction

Indexed keywords

ADRENALIN; ANGIOTENSIN II; BONE MORPHOGENETIC PROTEIN 9; BOSENTAN; BRADYKININ; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENRASENTAN; G PROTEIN COUPLED RECEPTOR; INOSITOL 1,4,5 TRISPHOSPHATE; INSULIN; INTERLEUKIN 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NATRIURETIC FACTOR; NITRIC OXIDE; PHOSPHOLIPASE C; PLACEBO; PREPROENDOTHELIN 1; PROSTAGLANDIN; REACTIVE OXYGEN METABOLITE; TEZOSENTAN; THROMBIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE; ADRENERGIC STIMULATION; ADRENERGIC SYSTEM; ARRHYTHMOGENESIS; CARDIOGENIC SHOCK; COMPARATIVE STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE NECROSIS; HUMAN; INFLAMMATION; INOTROPISM; LONG TERM CARE; NONHUMAN; NORADRENALIN RELEASE; OXIDATIVE STRESS; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VASCULAR SMOOTH MUSCLE;

ACUTE CORONARY SYNDROME; ANIMALS; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; ENDOTHELIN-1; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; RATS; RECEPTORS, ENDOTHELIN;

EID: 84883463035     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0b013e318283f65a     Document Type: Review

References (105)

1. Roger VL. Epidemiology of myocardial infarction. Med Clin North Am. 2007;91:537-552; ix.
2. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
3. Lüscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 2000;102:2434-2440.
4. Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol. 2008;86:485-498.
5. Macarthur H, Warner TD, Wood EG, et al. Endothelin-1 release from endothelial cells in culture is elevated both acutely and chronically by short periods of mechanical stretch. Biochem Biophys Res Commun. 1994;200:395-400.
6. Stow LR, Jacobs ME, Wingo CS, et al. Endothelin-1 gene regulation. FASEB J. 2011;25:16-28.
7. Battistini B, D'Orléans-Juste P, Sirois P. Endothelins: circulating plasma levels and presence in other biologic fluids. Lab Invest. 1993;68:600-628.
8. Molenaar P, O'Reilly G, Sharkey A, et al. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res. 1993;72:526-538.
9. Kelland NF, Kuc RE, McLean DL, et al. Endothelial cell-specific ETB receptor knockout: autoradiographic and histological characterisation and crucial role in the clearance of endothelin-1. Can J Physiol Pharmacol. 2010;88:644-651.
10. Meyer M, Lehnart S, Pieske B, et al. Influence of endothelin 1 on human atrial myocardium-myocardial function and subcellular pathways. Basic Res Cardiol. 1996;91:86-93.
11. Kolettis TM, Kyriakides ZS, Zygalaki E, et al. Endothelin system and atrial fibrillation post-cardiac surgery. J Interv Card Electrophysiol. 2008;21:203-208.
12. Takanashi M, Endoh M. Characterization of positive inotropic effect of endothelin on mammalian ventricular myocardium. Am J Physiol. 1991;261(3 Pt 2):H611-H619.
13. Dashwood MR, Tsui JC. Further evidence for a role of endothelin-1 (ET-1) in critical limb ischaemia. J Cell Commun Signal. 2011;5:45-49.
14. Thorin E, Webb DJ. Endothelium-derived endothelin-1. Pflugers Arch. 2010;459:951-958.
15. Liu Y, Gutterman DD. Vascular control in humans: focus on the coronary microcirculation. Basic Res Cardiol. 2009;104:211-227.
16. Dancu MB, Tarbell JM. Coronary endothelium expresses a pathologic gene pattern compared to aortic endothelium: correlation of asynchronous hemodynamics and pathology in vivo. Atherosclerosis. 2007;192:9-14.
17. Kyriakides ZS, Kremastinos DT, Bofilis E, et al. Endogenous endothelin maintains coronary artery tone by endothelin type A receptor stimulation in patients undergoing coronary arteriography. Heart. 2000;84:176-182.
18. Kinlay S, Behrendt D, Wainstein M, et al. Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation. 2001;104:1114-1118.
19. Lerman A, Holmes DR Jr, Bell MR, et al. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation. 1995;92:2426-2431.
20. Iglarz M, Clozel M. Mechanisms of ET-1-induced endothelial dysfunction. J Cardiovasc Pharmacol. 2007;50:621-628.
21. MacKenzie A. Endothelium-derived vasoactive agents, AT1 receptors and inflammation. Pharmacol Ther. 2011;131:187-203.
22. Kähler J, Ewert A, Weckmüller J, et al. Oxidative stress increases endothelin-1 synthesis in human coronary artery smooth muscle cells. J Cardiovasc Pharmacol. 2001;38:49-57.
23. Piechota A, Polanczyk A, Goraca A. Role of endothelin-1 receptor blockers on hemodynamic parameters and oxidative stress. Pharmacol Rep. 2010;62:28-34.
24. Dong F, Zhang X, Wold LE, et al. Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1. Br J Pharmacol. 2005;145:323-333.
25. Rossi GP, Colonna S, Pavan E, et al. Endothelin-1 and its mRNA in the wall layers of human arteries ex vivo. Circulation. 1999;99:1147-1155.
26. Simeone SM, Li MW, Paradis P, et al. Vascular gene expression in mice overexpressing human endothelin-1 targeted to the endothelium. Physiol Genomics. 2011;43:148-160.
27. Barton M, Haudenschild CC, d'Uscio LV, et al. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A. 1998;95:14367-14372.
28. Kanie N, Kamata K. Effects of chronic administration of the novel endothelin antagonist J-104132 on endothelial dysfunction in streptozotocin-induced diabetic rat. Br J Pharmacol. 2002;135:1935-1942.
29. Best PJ, McKenna CJ, Hasdai D, et al. Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia. Circulation. 1999;99:1747-1752.
30. Raichlin E, Prasad A, Mathew V, et al. Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension. 2008;52:522-528.
31. Reriani M, Raichlin E, Prasad A, et al. Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation. 2010;122:958-966.
32. Kleinbongard P, B̈se D, Baars T, et al. Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation. Circ Res. 2011;108:344-352.
33. Kleinbongard P, Konorza T, B̈se D, et al. Lessons from human coronary aspirate. J Mol Cell Cardiol. 2012;52:890-896.
34. Tsuji S, Sawamura A, Watanabe H, et al. Plasma endothelin levels during myocardial ischemia and reperfusion. Life Sci. 1991;48:1745-1749.
35. Watanabe T, Suzuki N, Shimamoto N, et al. Endothelin in myocardial infarction. Nature. 1990;344:114.
36. Watanabe T, Suzuki N, Shimamoto N, et al. Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. Circ Res. 1991;69:370-377.
37. Loennechen JP, Støylen A, Beisvag V, et al. Regional expression of endothelin- 1, ANP, IGF-1, and LV wall stress in the infarcted rat heart. Am J Physiol Heart Circ Physiol. 2001;280:H2902-H2910.
38. Miyauchi T, Yanagisawa M, Tomizawa T, et al. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet. 1989;2:53-54.
39. Stewart DJ, Kubac G, Costello KB, et al. Increased plasma endothelin- 1 in the early hours of acute myocardial infarction. J Am Coll Cardiol. 1991;18:38-43.
40. Yasuda M, Kohno M, Tahara A, et al. Circulating immunoreactive endothelin in ischemic heart disease. Am Heart J. 1990;119:801-806.
41. Tønnessen T, Naess PA, Kirkebøen KA, et al. Release of endothelin from the porcine heart after short term coronary artery occlusion. Cardiovasc Res. 1993;27:1482-1485.
42. Wang QD, Hemsén A, Li XS, et al. Local overflow and enhanced tissue content of endothelin following myocardial ischaemia and reperfusion in the pig: modulation by L-arginine. Cardiovasc Res. 1995;29:44-49.
43. Tønnessen T, Giaid A, Saleh D, et al. Increased in vivo expression and production of endothelin-1 by porcine cardiomyocytes subjected to ischemia. Circ Res. 1995;76:767-772.
44. Yip HK, Wu CJ, Chang HW, et al. Prognostic value of circulating levels of endothelin-1 in patients after acute myocardial infarction undergoing primary coronary angioplasty. Chest. 2005;127:1491-1497.
45. Omland T, Lie RT, Aakvaag A, et al. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation. 1994;89:1573-1579.
46. Baltogiannis GG, Tsalikakis DG, Mitsi AC, et al. Endothelin receptor-a blockade decreases ventricular arrhythmias after myocardial infarction in rats. Cardiovasc Res. 2005;67:647-654.
47. Clozel M, Qiu C, Qiu CS, et al. Short-term endothelin receptor blockade with tezosentan has both immediate and long-term beneficial effects in rats with myocardial infarction. J Am Coll Cardiol. 2002;39:142-147.
48. Kolettis TM, Baltogiannis GG, Tsalikakis DG, et al. Effects of dual endothelin receptor blockade on sympathetic activation and arrhythmogenesis during acute myocardial infarction in rats. Eur J Pharmacol. 2008;580:241-249.
49. Gonon AT, Wang QD, Pernow J. The endothelin A receptor antagonist LU 135252 protects the myocardium from neutrophil injury during ischaemia/ reperfusion. Cardiovasc Res. 1998;39:674-682.
50. López Farré A, Riesco A, Espinosa G, et al. Effect of endothelin-1 on neutrophil adhesion to endothelial cells and perfused heart. Circulation. 1993;88:1166-1171.
51. Ozdemir R, Parlakpinar H, Polat A, et al. Selective endothelin a (ETA) receptor antagonist (BQ-123) reduces both myocardial infarct size and oxidant injury. Toxicology. 2006;219:142-149.
52. Goyal SN, Bharti S, Arora S, et al. Endothelin receptor antagonist BQ-123 ameliorates myocardial ischemic-reperfusion injury in rats: a hemodynamic, biochemical, histopathological and electron microscopic evidence. Biomed Pharmacother. 2010;64:639-646.
53. Singh AD, Amit S, Kumar OS, et al. Cardioprotective effects of bosentan, a mixed endothelin type A and B receptor antagonist, during myocardial ischaemia and reperfusion in rats. Basic Clin Pharmacol Toxicol. 2006;98:604-610.
54. Wang ZY, Zhang W, Li XZ, et al. CPU0213, a novel endothelin type A and type B receptor antagonist, protects against myocardial ischemia/reperfusion injury in rats. Braz J Med Biol Res. 2011;44:1148-1155.
55. Adlbrecht C, Andreas M, Redwan B, et al. Systemic endothelin receptor blockade in ST-segment elevation acute coronary syndrome protects the microvasculature: a randomised pilot study. EuroIntervention. 2012;7:1386-1395.
56. Nagayama T, Kuwakubo F, Matsumoto T, et al. Role of endogenous endothelins in catecholamine secretion in the rat adrenal gland. Eur J Pharmacol. 2000;406:69-74.
57. Isaka M, Kudo A, Imamura M, et al. Endothelin receptors, localized in sympathetic nerve terminals of the heart, modulate norepinephrine release and reperfusion arrhythmias. Basic Res Cardiol. 2007;102:154-162.
58. Yamamoto S, Matsumoto N, Kanazawa M, et al. Different contributions of endothelin-A and endothelin-B receptors in postischemic cardiac dysfunction and norepinephrine overflow in rat hearts. Circulation. 2005;111:302-309.
59. Bibli SI, Toli EV, Vilaeti AD, et al. Endothelin-B receptors and left ventricular dysfunction after regional versus global ischaemia-reperfusion in rat hearts. Cardiol Res Pract. 2012;2012:986813.
60. Oikonomidis DL, Tsalikakis DG, Baltogiannis GG, et al. Endothelin-B receptors and ventricular arrhythmogenesis in the rat model of acute myocardial infarction. Basic Res Cardiol. 2010;105:235-245.
61. Proven A, Roderick HL, Conway SJ, et al. Inositol 1,4,5-trisphosphate supports the arrhythmogenic action of endothelin-1 on ventricular cardiac myocytes. J Cell Sci. 2006;119(Pt 16):3363-3375.
62. Merkely B, Gellér L, Tóth M, et al. Mechanism of endothelin-induced malignant ventricular arrhythmias in dogs. J Cardiovasc Pharmacol. 1998;31(suppl 1):S437-S439.
63. Washizuka T, Horie M, Watanuki M, et al. Endothelin-1 inhibits the slow component of cardiac delayed rectifier K+ currents via a pertussis toxin-sensitive mechanism. Circ Res. 1997;81:211-218.
64. Duru F, Barton M, Lüscher TF, et al. Endothelin and cardiac arrhythmias: do endothelin antagonists have a therapeutic potential as antiarrhythmic drugs? Cardiovasc Res. 2001;49:272-280.
65. Oikonomidis DL, Baltogiannis GG, Kolettis TM. Do endothelin receptor antagonists have an antiarrhythmic potential during acute myocardial infarction? Evidence from experimental studies. J Interv Card Electrophysiol. 2010;28:157-165.
66. Opitz CF, Finn PV, Pfeffer MA, et al. Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat: increased electrical stability independent of myocardial salvage. J Am Coll Cardiol. 1998;32:261-267.
67. Sharif I, Kane KA, Wainwright CL. Endothelin and ischaemic arrhythmiasantiarrhythmic or arrhythmogenic? Cardiovasc Res. 1998;39:625-632.
68. Bugge E, Ytrehus K. Endothelin-1 can reduce infarct size through protein kinase C and KATP channels in the isolated rat heart. Cardiovasc Res. 1996;32:920-929.
69. Wang P, Gallagher KP, Downey JM, et al. Pretreatment with endothelin-1 mimics ischemic preconditioning against infarction in isolated rabbit heart. J Mol Cell Cardiol. 1996;28:579-588.
70. Gourine AV, Molosh AI, Poputnikov D, et al. Endothelin-1 exerts a preconditioning- like cardioprotective effect against ischaemia/reperfusion injury via the ET(A) receptor and the mitochondrial K(ATP) channel in the rat in vivo. Br J Pharmacol. 2005;144:331-337.
71. Tawa M, Fukumoto T, Ohkita M, et al. Effects of exogenous big endothelin- 1 on postischemic cardiac dysfunction and norepinephrine overflow in rat hearts. Hypertens Res. 2011;34:218-224.
72. Tawa M, Fukumoto T, Ohkita M, et al. Contribution of nitric oxide in big endothelin-1-induced cardioprotective effects on ischemia/reperfusion injury in rat hearts. J Cardiovasc Pharmacol. 2011;57:575-578.
73. Kolettis TM. Endothelin-1 during myocardial ischaemia: a double-edged sword? Hypertens Res. 2011;34:170-172.
74. Dec GW. Management of acute decompensated heart failure. Curr Probl Cardiol. 2007;32:321-366.
75. Schalcher C, Cotter G, Reisin L, et al. The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure. Am Heart J. 2001;142:340-349.
76. O'Connor CM, Gattis WA, Adams KF Jr, et al.; Randomized Intravenous TeZosentan Study-4 Investigators. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol. 2003;41:1452-1457.
77. McMurray JJ, Teerlink JR, Cotter G, et al.; VERITAS Investigators. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA. 2007;298:2009-2019.
78. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002;53:31-47.
79. Frangogiannis NG. Chemokines in the ischemic myocardium: from inflammation to fibrosis. Inflamm Res. 2004;53:585-595.
80. Sun Y, Weber KT. Infarct scar: a dynamic tissue. Cardiovasc Res. 2000;46: 250-256.
81. Katwa LC, Guarda E, Weber KT. Endothelin receptors in cultured adult rat cardiac fibroblasts. Cardiovasc Res. 1993;27:2125-2129.
82. Guarda E, Katwa LC, Myers PR, et al. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res. 1993;27:2130-2134.
83. Markewitz BA, Farrukh IS, Chen Y, et al. Regulation of endothelin-1 synthesis in human pulmonary arterial smooth muscle cells. Effects of transforming growth factor-beta and hypoxia. Cardiovasc Res. 2001;49:200-206.
84. Little PJ, Burch ML, Getachew R, et al. Endothelin-1 stimulation of proteoglycan synthesis in vascular smooth muscle is mediated by endothelin receptor transactivation of the transforming growth factor-[beta] type I receptor. J Cardiovasc Pharmacol. 2010;56:360-368.
85. Rodriguez-Vita J, Ruiz-Ortega M, Rupérez M, et al. Endothelin-1, via ETA receptor and independently of transforming growth factor-beta, increases the connective tissue growth factor in vascular smooth muscle cells. Circ Res. 2005;97:125-134.
86. Fraccarollo D, Hu K, Galuppo P, et al. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. Circulation. 1997;96:3963-3973.
87. Nguyen QT, Cernacek P, Sirois MG, et al. Long-term effects of nonselective endothelin A and B receptor antagonism in postinfarction rat: importance of timing. Circulation. 2001;104:2075-2081.
88. Fraccarollo D, Galuppo P, Bauersachs J, et al. Collagen accumulation after myocardial infarction: effects of ETA receptor blockade and implications for early remodeling. Cardiovasc Res. 2002;54:559-567.
89. Hu K, Gaudron P, Schmidt TJ, et al. Aggravation of left ventricular remodeling by a novel specific endothelin ET(A) antagonist EMD94246 in rats with experimental myocardial infarction. J Cardiovasc Pharmacol. 1998;32:505-508.
90. Oie E, Yndestad A, Robins SP, et al. Early intervention with a potent endothelin-A/endothelin-B receptor antagonist aggravates left ventricular remodeling after myocardial infarction in rats. Basic Res Cardiol. 2002;97:239-247.
91. Sakai S, Miyauchi T, Yamaguchi I. Long-term endothelin receptor antagonist administration improves alterations in expression of various cardiac genes in failing myocardium of rats with heart failure. Circulation. 2000;101:2849-2853.
92. Miyauchi T, Fujimori A, Maeda S, et al. Chronic administration of an endothelin- A receptor antagonist improves exercise capacity in rats with myocardial infarction-induced congestive heart failure. J Cardiovasc Pharmacol. 2004;44(suppl 1):S64-S67.
93. Podesser BK, Siwik DA, Eberli FR, et al. ET(A)-receptor blockade prevents matrix metalloproteinase activation late postmyocardial infarction in the rat. Am J Physiol Heart Circ Physiol. 2001;280:H984-H991.
94. Fraccarollo D, Bauersachs J, Kellner M, et al. Cardioprotection by longterm ET(A) receptor blockade and ACE inhibition in rats with congestive heart failure: mono- versus combination therapy. Cardiovasc Res. 2002;54:85-94.
95. Sakai S, Miyauchi T, Sakurai T, et al. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. Circulation. 1996;93:1214-1222.
96. Kozák M, Izákovicová Hollá L, Krivan L, et al. Endothelin-1 gene polymorphism in patients with malignant arrhythmias. J Cardiovasc Pharmacol. 2004;44(suppl 1):S92-S95.
97. Yang LL, Gros R, Kabir MG, et al. Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice. Circulation. 2004;109:255-261.
98. Mueller EE, Momen A, Massé S, et al. Electrical remodelling precedes heart failure in an endothelin-1-induced model of cardiomyopathy. Cardiovasc Res. 2011;89:623-633.
99. Vetter D, Shaw SG, Brandes RP, et al. Beneficial cardiovascular effects of endothelin ET(A) receptor blockade in established long-term heart failure after myocardial infarction. Exp Biol Med (Maywood). 2006;231:857-860.
100. Cowburn PJ, Cleland JG, McArthur JD, et al. Short-term haemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure. Lancet. 1998;352:201-202.
101. Kiowski W, Sütsch G, Hunziker P, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 1995;346:732-736.
102. Kelland NF, Webb DJ. Clinical trials of endothelin antagonists in heart failure: publication is good for the public health. Heart. 2007;93:2-4.
103. Kirkby NS, Hadoke PW, Bagnall AJ, et al. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol. 2008;153:1105-1119.
104. Kohan DE, Cleland JG, Rubin LJ, et al. Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? Life Sci. 2012;91:528-539.
105. Barton M, Kohan DE. Endothelin antagonists in clinical trials: lessons learned. Contrib Nephrol. 2011;172:255-260.